Is Vertex Pharmaceuticals Stock a Buy in 2025?
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Vertex Pharmaceuticals price target lowered to $533 from $535 at Piper Sandler
Piper Sandler lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $533 from $535 and keeps an Overweight rating on the shares ...
Benzinga.com13d
Vertex's Pain Drug: Big Pharma's Next Major Success?
Vertex Pharmaceuticals VRTX is a biotechnology company with a strong track record of success in developing treatments for cystic fibrosis (CF). Vertex is strategically expanding into the pain ...
Vertex Pharmaceuticals price target lowered to $450 from $456 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $456 and keeps an Equal Weight rating on the ...
Benzinga.com19d
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals
Ratings for Vertex Pharmaceuticals VRTX were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of ...
Seeking Alpha29d
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the ...